Table 1.
Baseline characteristics of enrolled patients.
| Total (N = 10) | |
|---|---|
| Age (years) | 64.5 (60.3–68.5) |
| Sex, male | 4 (40%) |
| Pathology | |
| PTC | 6 (60%) |
| FTC | 2 (20%) |
| PDTC | 2 (20%) |
| Initial cancer stagea | |
| I | 2 (22%) |
| II | 1 (11%) |
| IV | 6 (67%) |
| Cumulative RAI dose (mCi) | 240 (163–519) |
| Previous sorafenib treatment (yes) | 2 (20%) |
| Duration between initial diagnosis to lenvatinib treatment (years) | 5.0 (2.5–6.8) |
| Target lesions | |
| Lymph node | 5 (50%) |
| Lung | 4 (40%) |
| Bone | 1 (20%) |
| Lenvatinib maintenance dose (mg) | 19 (14–20) |
| Best response from lenvatinib | |
| Partial response | 2 (20%) |
| Stable disease | 8 (80%) |
Continuous variables are presented as median (interquartile range) and categorical variables as numbers (percentages).
PTC papillary thyroid carcinoma, FTC follicular thyroid carcinoma, PDTC poor differentiated thyroid carcinoma, RAI radioactive iodine.
aInitial stage by 8th TNM staging system could be assessed in 9 patients.